Heron Therapeutics (HRTX) Return on Capital Employed (2011 - 2026)

Heron Therapeutics has reported Return on Capital Employed for 16 years, with the latest figure at 6.51% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 406.0% year-over-year to 6.51%; the trailing twelve-month figure through Mar 2026 stood at 6.51% (down 406.0% YoY), and the FY2025 full-year result was 1.71%, up 674.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 6.51%, down from 1.62% in the prior quarter.
• The five-year high for Return on Capital Employed was 1.06% in Q3 2025, with the low at 145.75% in Q2 2022.
• Historically, Return on Capital Employed has averaged 58.02% across 5 years, with a median of 56.86% in 2024.
• Annual changes were most pronounced in 2022 — Return on Capital Employed tumbled 6142 bps — and 2024, when it soared 7706 bps.
• Heron Therapeutics' Return on Capital Employed stood at 97.52% in 2022, then gained by 22 bps to 75.68% in 2023, then soared by 89 bps to 8.51% in 2024, then soared by 81 bps to 1.62% in 2025, then sank by 301 bps to 6.51% in 2026.
• The last three Return on Capital Employed figures came in at 6.51% (Q1 2026), 1.62% (Q4 2025), and 1.06% (Q3 2025), per Business Quant data.